Article Details

Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a ...

Retrieved on: 2024-09-23 19:49:11

Tags for this article:

Click the tags to see associated articles and topics

Biotech company Eradivir closes $10.25M Series A funding round to complete Phase 2a .... View article details on hiswai:

Excerpt

Eradivir's goal is to focus the power of the immune system to treat disease. Its small-molecule, bispecific immunotherapy tethers a patient's ...

Article found on: www.purdue.edu

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up